AmorChem backs research on central nervous system diseases

Canadian life sciences venture capital firm AmorChem has invested in a research program from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec.

4 June 2020•5 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles